BIND Therapeutics (NASDAQ:BIND) : Traders are bullish on BIND Therapeutics (NASDAQ:BIND) as it has outperformed the S&P 500 by a wide margin of 38.05% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 39.2%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 40.98% in the last 1 week, and is up 40.28% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -90.21% from its 1 Year high price. On Jul 14, 2015, the shares registered one year high at $5.98 and the one year low was seen on May 17, 2016. The 50-Day Moving Average price is $0.44 and the 200 Day Moving Average price is recorded at $1.33.
The stock has recorded a 20-day Moving Average of 26.23% and the 50-Day Moving Average is 13.26%.
BIND Therapeutics (NASDAQ:BIND): stock turned positive on Friday. Though the stock opened at $0.5343, the bulls momentum made the stock top out at $0.6005 level for the day. The stock recorded a low of $0.522 and closed the trading day at $0.5611, in the green by 2.02%. The total traded volume for the day was 921,114. The stock had closed at $0.55 in the previous days trading.
BIND Therapeutics, Inc. is a clinical-stage nano-medicine platform company. The Company is engaged in developing a pipeline of Accurins. The Company utilizes its Medicinal Nano-engineering platform to develop a pipeline of Accurins in oncology. The Companys products include BIND-014 and BIND-510. The Companys lead drug candidate BIND-014 is a prostate-specific membrane antigen (PSMA)-targeted Accurin that contains docetaxel, a clinically validated cancer chemotherapy drug. PSMA is a clinically validated tumor marker expressed on prostate cancer cells and the blood vessels of many types of non-prostate solid tumors. It has completed a Phase I clinical trial evaluating BIND-014 in patients with advanced and metastatic solid tumors. The Companys product candidate BIND-510 is also a PSMA-targeted Accurin containing vincristine. BIND-510 is designed to concentrate high levels of vincristine in tumors while limiting exposure to healthy tissue.